Literature DB >> 32327896

A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor.

Paola Sanchez Garay1, Gabriela Zuniga2, Robert Lichtenberg1.   

Abstract

Entities:  

Year:  2020        PMID： 32327896      PMCID： PMC7164991          DOI： 10.2337/cd19-0055

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  16 in total

1.  Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin.

Authors:  Paris Roach; Paul Skierczynski
Journal:  Diabetes Care       Date:  2015-10-30       Impact factor: 19.112

2.  The Ketogenic Diet for Obesity and Diabetes-Enthusiasm Outpaces Evidence.

Authors:  Shivam Joshi; Robert J Ostfeld; Michelle McMacken
Journal:  JAMA Intern Med       Date:  2019-09-01       Impact factor: 21.873

3.  Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.

Authors:  Stephanie Dizon; Erin J Keely; Janine Malcolm; Amel Arnaout
Journal:  Can J Diabetes       Date:  2017-08-07       Impact factor: 4.190

4.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Authors:  Yehuda Handelsman; Robert R Henry; Zachary T Bloomgarden; Sam Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Ele Ferrannini; Vivian A Fonseca; Alan J Garber; George Grunberger; Derek LeRoith; Guillermo E Umpierrez; Matthew R Weir
Journal:  Endocr Pract       Date:  2016-06-01       Impact factor: 3.443

Review 5.  SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

Authors:  Kelly R Burke; Christine A Schumacher; Spencer E Harpe
Journal:  Pharmacotherapy       Date:  2017-01-16       Impact factor: 4.705

6.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.

Authors:  Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-06-15       Impact factor: 19.112

Review 7.  Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets.

Authors:  A Paoli; A Rubini; J S Volek; K A Grimaldi
Journal:  Eur J Clin Nutr       Date:  2013-06-26       Impact factor: 4.016

8.  A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.

Authors:  Ashley M Zurek; Raghunandan Yendapally; Elizabeth M Urteaga
Journal:  Diabetes Spectr       Date:  2017-05

9.  Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.

Authors:  D Taylor Gammons; Francis L Counselman
Journal:  Clin Pract Cases Emerg Med       Date:  2018-01-11

10.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232
View more
  3 in total

1.  SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.

Authors:  Fateen Ata; Zohaib Yousaf; Adeel Ahmad Khan; Almurtada Razok; Jaweria Akram; Elrazi Awadelkarim Hamid Ali; Ahmed Abdalhadi; Diaeldin Abdelgalil Ibrahim; Dabia Hamad S H Al Mohanadi; Mohammed I Danjuma
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

2.  Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor.

Authors:  Mohamed Alhemeiri; Eiman Alseddeeqi
Journal:  Case Rep Endocrinol       Date:  2022-03-02

3.  Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin).

Authors:  Azka Latif; Aheli Arce Gastelum; Akshat Sood; Joseph Thilumala Reddy
Journal:  BMJ Case Rep       Date:  2020-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.